Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 101

1.
2.

Tumor necrosis factor alpha stimulates cathepsin K and V activity via juxtacrine monocyte-endothelial cell signaling and JNK activation.

Keegan PM, Wilder CL, Platt MO.

Mol Cell Biochem. 2012 Aug;367(1-2):65-72. doi: 10.1007/s11010-012-1320-0. Epub 2012 May 5.

3.

Manipulating substrate and pH in zymography protocols selectively distinguishes cathepsins K, L, S, and V activity in cells and tissues.

Wilder CL, Park KY, Keegan PM, Platt MO.

Arch Biochem Biophys. 2011 Dec 1;516(1):52-7. doi: 10.1016/j.abb.2011.09.009. Epub 2011 Sep 29.

4.

Regulation of elastinolytic cysteine proteinase activity in normal and cathepsin K-deficient human macrophages.

Punturieri A, Filippov S, Allen E, Caras I, Murray R, Reddy V, Weiss SJ.

J Exp Med. 2000 Sep 18;192(6):789-99.

5.
6.

BSP and RANKL induce osteoclastogenesis and bone resorption synergistically.

Valverde P, Tu Q, Chen J.

J Bone Miner Res. 2005 Sep;20(9):1669-79. Epub 2005 May 16.

7.

Proteinase expression during differentiation of human osteoclasts in vitro.

Blair HC, Sidonio RF, Friedberg RC, Khan NN, Dong SS.

J Cell Biochem. 2000 Jun 12;78(4):627-37.

PMID:
10861860
8.

Proteolytic processing and polarized secretion of tartrate-resistant acid phosphatase is altered in a subpopulation of metaphyseal osteoclasts in cathepsin K-deficient mice.

Zenger S, Hollberg K, Ljusberg J, Norgård M, Ek-Rylander B, Kiviranta R, Andersson G.

Bone. 2007 Nov;41(5):820-32. Epub 2007 Jul 19.

PMID:
17765026
10.

RANKL coordinates cell cycle withdrawal and differentiation in osteoclasts through the cyclin-dependent kinase inhibitors p27KIP1 and p21CIP1.

Sankar U, Patel K, Rosol TJ, Ostrowski MC.

J Bone Miner Res. 2004 Aug;19(8):1339-48. Epub 2004 Mar 29.

11.

Proteolytic activity of human osteoclast cathepsin K. Expression, purification, activation, and substrate identification.

Bossard MJ, Tomaszek TA, Thompson SK, Amegadzie BY, Hanning CR, Jones C, Kurdyla JT, McNulty DE, Drake FH, Gowen M, Levy MA.

J Biol Chem. 1996 May 24;271(21):12517-24.

12.

Double stranded RNA-dependent protein kinase is involved in osteoclast differentiation of RAW264.7 cells in vitro.

Teramachi J, Morimoto H, Baba R, Doi Y, Hirashima K, Haneji T.

Exp Cell Res. 2010 Nov 15;316(19):3254-62. doi: 10.1016/j.yexcr.2010.08.006. Epub 2010 Aug 20.

PMID:
20728438
13.
14.

Proteolytic excision of a repressive loop domain in tartrate-resistant acid phosphatase by cathepsin K in osteoclasts.

Ljusberg J, Wang Y, Lång P, Norgård M, Dodds R, Hultenby K, Ek-Rylander B, Andersson G.

J Biol Chem. 2005 Aug 5;280(31):28370-81. Epub 2005 Jun 1.

15.
16.

A pterostilbene derivative suppresses osteoclastogenesis by regulating RANKL-mediated NFκB and MAPK signaling in RAW264.7 cells.

Nikhil K, Sharan S, Roy P.

Pharmacol Rep. 2015 Dec;67(6):1264-72. doi: 10.1016/j.pharep.2015.05.009. Epub 2015 May 30.

PMID:
26481551
17.

Ellagic acid inhibits RANKL-induced osteoclast differentiation by suppressing the p38 MAP kinase pathway.

Rantlha M, Sagar T, Kruger MC, Coetzee M, Deepak V.

Arch Pharm Res. 2017 Jan;40(1):79-87. doi: 10.1007/s12272-016-0790-0. Epub 2016 Jul 6.

PMID:
27384064
18.

Identification of a human peripheral blood monocyte subset that differentiates into osteoclasts.

Komano Y, Nanki T, Hayashida K, Taniguchi K, Miyasaka N.

Arthritis Res Ther. 2006;8(5):R152.

19.

Bromo-honaucin A inhibits osteoclastogenic differentiation in RAW 264.7 cells via Akt and ERK signaling pathways.

Sapkota M, Li L, Choi H, Gerwick WH, Soh Y.

Eur J Pharmacol. 2015 Dec 15;769:100-9. doi: 10.1016/j.ejphar.2015.11.003. Epub 2015 Nov 10.

20.

Cathepsins in the osteoclast.

Goto T, Yamaza T, Tanaka T.

J Electron Microsc (Tokyo). 2003;52(6):551-8. Review.

PMID:
14756243

Supplemental Content

Support Center